Patient characteristics
. | No. . | % . |
|---|---|---|
| Patients | 121 | 100 |
| Age, median (range), y | 68 (31-89) | — |
| Sex | ||
| Male | 61 | 50.4 |
| Female | 60 | 49.5 |
| Stage | ||
| I | 4 | 3.3 |
| IIA | 31 | 25.6 |
| IIIA | 67 | 55.3 |
| IIIB | 19 | 15.7 |
| Immunologic subtype | ||
| IgG | 62 | 51.2 |
| IgA | 34 | 28.0 |
| IgD | 1 | 0.8 |
| BJ | 19 | 15.7 |
| Nonsecretory | 5 | 4.1 |
| Bone disease | ||
| A, no lytic lesions or osteoporosis | 10 | 8.2 |
| B, 1-3 lytic lesions | 28 | 23.1 |
| C, more than 3 lytic lesions or fractures | 83 | 68.5 |
| Hemoglobin level, less than 10 g/dL | 36 | 29.7 |
| Calcium level, greater than 3 mM | 12 | 9.9 |
| Albumin level, less than 30 g/L | 14 | 11.5 |
| β2-microglobulin level, greater than 3 mg/L | 64 | 52.8 |
| CRP level, greater than 10 mg/L | 32 | 26.4 |
| IL-6 level, greater than 30 pg/mL | 52 | 42.9 |
. | No. . | % . |
|---|---|---|
| Patients | 121 | 100 |
| Age, median (range), y | 68 (31-89) | — |
| Sex | ||
| Male | 61 | 50.4 |
| Female | 60 | 49.5 |
| Stage | ||
| I | 4 | 3.3 |
| IIA | 31 | 25.6 |
| IIIA | 67 | 55.3 |
| IIIB | 19 | 15.7 |
| Immunologic subtype | ||
| IgG | 62 | 51.2 |
| IgA | 34 | 28.0 |
| IgD | 1 | 0.8 |
| BJ | 19 | 15.7 |
| Nonsecretory | 5 | 4.1 |
| Bone disease | ||
| A, no lytic lesions or osteoporosis | 10 | 8.2 |
| B, 1-3 lytic lesions | 28 | 23.1 |
| C, more than 3 lytic lesions or fractures | 83 | 68.5 |
| Hemoglobin level, less than 10 g/dL | 36 | 29.7 |
| Calcium level, greater than 3 mM | 12 | 9.9 |
| Albumin level, less than 30 g/L | 14 | 11.5 |
| β2-microglobulin level, greater than 3 mg/L | 64 | 52.8 |
| CRP level, greater than 10 mg/L | 32 | 26.4 |
| IL-6 level, greater than 30 pg/mL | 52 | 42.9 |
Ig indicates immunoglobulin; BJ, Bence-Jones